The treatment practices for endometrial cancer have significantly changed over the last two decades. Nowadays, in addition to standard pathology, additional tests are performed to understand the behaviour of tumour so that personalized treatment can be advised for every patient. This approach ensures that patients with good cancer cell features receive minimum essential radiotherapy or surgery treatment with fewer side effects, while those with poor cell features undergo more aggressive treatment to improve their chances of survival.
However, this approach is not widely adopted in Asian countries. To address this, investigators are launching a project to gather data from various hospitals across Asia. The project aims to understand how different cancer cell factors impact treatment decisions and identify better ways to select additional treatment plans based on a patient's cancer cell features.
The project will gather data from around 250-300 patients who were evaluated or treated between January 2021 and December 2023. It will run for two years to improve our understanding and gain insights into the best ways to treat endometrial cancer.
Eligibility
Sex
FEMALE
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
\- Patients who were diagnosed to have EC and have access to standard histopathological reports and availability of treatment decisions.
Exclusion Criteria:
\- Patients with final histopathological diagnosis of any other gynecological malignancy other than EC and its subtypes.
Primary outcome measure(s)
To study the Clinico-pathological characteristics in Endometrial Cancer — 24 months Proportion of Endometrial Cancer Molecular Subtypes (POLEmut, MMR-deficient, NSMP, p53 abnormal) and distribution of adjuvant radiation therapy types received (vaginal brachytherapy, external beam radiation therapy \[EBRT\], or combined radiation with chemotherapy) reported at treatment completion.
To study molecular characteristics in Endometrial Cancer. — 24 Months Proportion of Endometrial Cancer Cases by Tumor Grade, Histological Type, and Tumor Stage
To study the Clinicopathologic characteristics impact on treatment decision making across Asian regions — 24 Months proportion of patients who exhibit predefined clinicopathologic characteristics with percentages reported for each participating Asian region
To study molecular characteristics impact on treatment decision making across Asian regions. — 24 Months Proportion of participants whose treatment decisions are influenced by molecular characteristics. Data will be summarized by Asian region and analyzed in relation to clinical and demographic characteristics to assess the overall impact on treatment decision making.
Trial sites (2)
Facility
City
Region
Status
Tata Memorial Hospital
Mumbai
Maharashtra
Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.